Global Alpha-1 Antitrypsin Drugs Market 2018-2022

Global Alpha-1 Antitrypsin Drugs Market 2018-2022

  • August 2018 •
  • 107 pages •
  • Report ID: 3816802 •
  • Format: PDF
About Alpha-1 Antitrypsin Drugs

Alpha-1 antitrypsin augmentation therapy is used for treating emphysema caused due to deficiency of alpha-1 antitrypsin proteins in the bloodstream.
Technavio’s analysts forecast the Global Alpha-1 Antitrypsin Drugs Market to grow at a CAGR of 10.64% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the alpha-1 antitrypsin drugs market. To calculate the market size, the report considers the revenue generated from the sales of alpha-1 antitrypsin drugs across the globe.

The market is divided into the following segments based on geography:
•Americas
•APAC
•EMEA

Technavio’s report, alpha-1 antitrypsin drugs market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
•Shire
•CSL
•GRIFOLS
•Kamada

Market driver
•Improving diagnosis of alpha-1 antitrypsin deficiency
•For a full, detailed list, view our report

Market challenge
•High cost of drugs
•For a full, detailed list, view our report

Market trend
•Strategic alliances and mergers
•For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.